Amikacin/fosfomycin inhalation system - Cardeas

Drug Profile

Amikacin/fosfomycin inhalation system - Cardeas

Alternative Names: AFIS; Amikacin/fosfomycin eFlow® Nebulizer system; eFlow Inline System

Latest Information Update: 18 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cardeas Pharma
  • Class Aminoglycosides; Antibacterials; Epoxy compounds; Organophosphorus compounds; Phosphonic acids; Phosphoric acid esters; Small molecules
  • Mechanism of Action Cell wall inhibitors; Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Pneumonia
  • No development reported Bronchitis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Bronchitis in Australia (Inhalation, Aerosol)
  • 01 Jul 2016 Cardeas Pharma completes a phase I pharmacokinetic trial in Healthy volunteers in USA (NCT02709265)
  • 01 Apr 2016 Cardeas Pharma initiates enrolment in a phase I pharmacokinetic trial in Healthy volunteers in USA (NCT02709265)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top